Homepage > Company > Media > Pharma News > 2022 > RedHill Touts Potential of Its Investigational Cancer Drug Against Omicron Subvariants

RedHill Touts Potential of Its Investigational Cancer Drug Against Omicron Subvariants

Israel-based RedHill Biopharma said that its dual-action investigational COVID-19 oral antiviral and anti-inflammatory drug opaganib has shown potential efficacy against the Omicron subvariants BA.2 and XE, but also against other emerging variants.

Citing in vitro research as well as results from a phase 2/3 study, the company said the sphingosine kinase-2 inhibitor showed “potent” efficacy against the Omicron COVID-19 variant. In the clinical trial, of hospitalized patients with severe COVID-19 pneumonia, the drug reduced mortality by 70 percent, the company said.

The FDA previously granted opaganib an Orphan Drug designation as a potential treatment for cholangiocarcinoma. But the company said it is now working with regulators in the U.S., Europe and the UK to find ways to gain approval for the treatment of COVID-19.

April 13, 2022

https://www.fdanews.com/

Read also

FDA approves AstraZeneca’s FASENRA for asthma in children

The expanded approval of FASENRA for use in younger patients comes after the regulator initially approved the therapy in 2017.

Candel wins FDA orphan drug designation for pancreatic cancer drug

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pa...

FDA Gives Fast Track Designation to LYT-200 in Advanced Head and Neck Cancers

LYT-200 is currently being investigated for those with solid tumors and hematologic malignancies.

Vertex to expand autoimmune and inflammatory disease pipeline with $4.9bn Alpine acquisition

Vertex Pharmaceuticals has announced its acquisition of Alpine Immune Sciences, a biotechnology company focused on developing and discovering protein-based immunotherapies, in a deal worth $4.9bn.